Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multicenter, Phase II Study to Evaluate Efficacy and Safety of the BiTE® Antibody Blinatumomab in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

NCT01466179 is registered in ClinicalTrials.gov with Amgen Research (Munich) GmbH as lead sponsor.

NCT NCT01466179
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01466179 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multicenter, Phase II Study to Evaluate Efficacy and Safety of the BiTE® Antibody Blinatumomab in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Lead sponsor
Amgen Research (Munich) GmbH
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2011
Completion date
January 31, 2017
Enrollment
225 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia